MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 235 filers reported holding MYRIAD GENETICS INC in Q2 2015. The put-call ratio across all filers is 1.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $54,411,000 | -5.2% | 3,264,023 | +17.0% | 0.01% | -16.7% |
Q3 2016 | $57,423,000 | -29.5% | 2,790,235 | +4.8% | 0.01% | -33.3% |
Q2 2016 | $81,487,000 | -20.3% | 2,662,989 | -2.5% | 0.02% | -25.0% |
Q1 2016 | $102,218,000 | -10.9% | 2,730,915 | +2.7% | 0.02% | -7.7% |
Q4 2015 | $114,757,000 | +9.9% | 2,658,881 | -4.6% | 0.03% | -3.7% |
Q3 2015 | $104,456,000 | +12.7% | 2,786,972 | +2.2% | 0.03% | +22.7% |
Q2 2015 | $92,712,000 | +62.1% | 2,727,612 | +68.8% | 0.02% | +57.1% |
Q1 2015 | $57,207,000 | +13.4% | 1,616,019 | +9.1% | 0.01% | +16.7% |
Q4 2014 | $50,435,000 | -12.3% | 1,480,758 | -0.7% | 0.01% | -25.0% |
Q3 2014 | $57,499,000 | +0.7% | 1,490,775 | +1.6% | 0.02% | 0.0% |
Q2 2014 | $57,113,000 | +11.8% | 1,467,442 | -1.8% | 0.02% | +6.7% |
Q1 2014 | $51,091,000 | +68.8% | 1,494,328 | +3.6% | 0.02% | +66.7% |
Q4 2013 | $30,263,000 | -11.7% | 1,442,462 | -1.0% | 0.01% | -25.0% |
Q3 2013 | $34,254,000 | +0.0% | 1,457,633 | +14.4% | 0.01% | -7.7% |
Q2 2013 | $34,237,000 | – | 1,274,183 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |